Introduction
============

Torque Teno Virus (TTV) was first discovered in 1997 in a patient with hepatitis of unknown etiology ([@B22]), and was assigned to the family of Anelloviridae ([@B17]; [@B27]). The prevalence of TTV in the general population was described to reach up to 90%, with detectability of the virus in peripheral blood (PB), stool, saliva, and pharyngeal mucus, suggesting several possible routes of transmission and a high probability of exposure ([@B24]; [@B7]; [@B20]; [@B5]; [@B23]). Although TTV apparently establishes long-lasting persistent infections and circulates in PB in most individuals, no convincing evidence for its potential pathogenicity in humans has been provided to date ([@B2]). The common occurrence of TTV in samples derived from whole PB and plasma raised the possibility that hematopoietic cells might serve as a reservoir for the virus, and a few studies indeed reported detection of TTV in B and T lymphocytes, monocytes and granulocytes, but neither in platelets nor in erythrocytes ([@B19]; [@B28]). Nevertheless, the sites of virus persistence and replication have remained uncertain due to the lack of conclusive evidence. The detection of TTV has not been clearly associated with any disease in humans, but a correlation between the virus levels in plasma and the degree of immunosuppression has been discussed in the context of decreased graft rejection rates observed in solid organ transplant recipients with high TTV titers ([@B6]; [@B26]). The correlation with immune reconstitution in the transplant setting is supported by observations of rising and subsequently decreasing TTV plasma levels in patients after lung or liver transplantation ([@B3]; [@B18]; [@B13]) and hematopoietic stem cell transplantation (HSCT) ([@B9]; [@B21]). Recent studies therefore discussed the possibility of exploiting TTV DNA levels in plasma or whole PB as a biomarker for the risk of severe immune reactions and immune recovery after HSCT ([@B1]; [@B12]; [@B30]). Although the potential clinical benefit of performing quantitative TTV monitoring in transplant recipients has been stressed in these studies, current evidence supporting this concept is rather limited. Additional studies would be required to corroborate previous observations and to provide more detailed insights pertaining to the mechanisms of TTV increase after engraftment to elucidate the potential role of the virus in the transplant setting.

In the present study, consecutive plasma samples derived from 43 pediatric allogeneic HSCT recipients were monitored for TTV levels over a time period of more than 1 year post-transplant. The potential site(s) of TTV replication in individual blood cell types were assessed by investigating the virus copy numbers in various leukocyte subsets isolated by flow-sorting. The study performed in pediatric HSCT recipients provides evidence for TTV replication in granulocytes which culminated around 100 days post-transplant. The onset and kinetics of virus replication appeared to correlate with the level of immunosuppression and the time course of granulocyte engraftment.

Patients and Methods
====================

Patients
--------

Archived plasma, stool, PB, and bone marrow (BM) specimens derived from pediatric allogeneic stem cell transplant recipients treated at the St. Anna Children's Hospital, Vienna, Austria, were used for the study. The specimens had been collected as part of routine diagnostic virus screening at consecutive time points starting before conditioning followed by collection at 7-day intervals until day +100, thereafter at 2 to 3 week intervals until day +360, and at less regular intervals after the first year post-transplant. Written informed consent was obtained from each of the 43 patients and/or the parents. The patient characteristics are listed in Table [1](#T1){ref-type="table"}. A control cohort including 60 immunocompetent patients treated at St. Anna Children's Hospital was studied in parallel. From these patients, residual anonymized PB samples remaining from routine laboratory analyses had been collected. Approval for analysis of TTV in the collected samples was obtained from the Ethics Committee (Medical University Vienna, Austria) EK Nr: 2069/2016. In addition, expired platelet concentrates from 14 donors were kindly provided for TTV testing by the Center for Blood Donations of the Austrian Red Cross.

###### 

Characteristics of the HSCT recipients investigated and TTV copies/ml plasma.

  Pat   Donor   Underlying disease   ATG   Cond.   ^a^CD3^+^   ^a^NK   GvHD grade   TTV^b^ Before HSCT 0   TTV^b^ Post-HSCT^c^   Log difference
  ----- ------- -------------------- ----- ------- ----------- ------- ------------ ---------------------- --------------------- ----------------
  1     UD      Malignant            Yes   MA      19          12      2            0                      8.87E+06              6.98
  2     MSD     Malignant            Yes   MA      27          20      1            0                      5.24E+07              7.72
  3     MSD     Malignant            Yes   MA      20          13      2            0                      4.75E+05              5.68
  4     MSD     Malignant            Yes   RIC     20          14      0            0                      2.86E+05              5.46
  5     UD      SCID                 Yes   RIC     62          20      1            0                      7.38E+03              3.87
  6     UD      Malignant            No    MA      13          13      0            0                      3.02E+07              7.48
  7     MMFD    SCID                 No    RIC     36          12      0            0                      4.40E+08              8.64
  8     MSD     Malignant            Yes   MA      11          11      2            0                      4.07E+09              9.61
  9     UD      Malignant            Yes   MA      27          27      0            0                      2.59E+08              8.41
  10    MMFD    Malignant            Yes   RIC     15          21      4            1.16E+04               5.31E+08              4.66
  11    UD      Malignant            No    MA      13          17      1            3.81E+05               1.22E+09              3.51
  12    UD      Malignant            No    MA      13          43      2            1.37E+04               2.43E+06              2.25
  13    UD      Malignant            Yes   RIC     20          13      0            9.85E+02               1.01E+09              6.01
  14    UD      Malignant            Yes   MA      26          16      2            4.24E+04               1.07E+08              3.40
  15    UD      SCID                 Yes   RIC     14          14      2            1.50E+03               1.01E+09              5.83
  16    MMFD    Malignant            No    RIC     27          20      0            7.01E+04               1.07E+08              3.84
  17    UD      Malignant            No    MA      13          9       1            6.42E+03               1.01E+09              4.82
  18    UD      Malignant            Yes   RIC     28          7       1            4.31E+03               4.89E+08              5.06
  19    UD      SCID                 Yes   RIC     13          13      1            6.45E+06               4.27E+08              1.67
  20    UD      SCID                 No    RIC     30          16      0            1.91E+07               4.97E+08              0.78
  21    UD      Malignant            Yes   MA      26          26      0            5.34E+03               6.88E+07              4.11
  22    MSD     Malignant            Yes   RIC     18          18      0            2.13E+07               2.13E+07              0.00
  23    UD      Malignant            Yes   RIC     69          10      0            4.65E+04               3.06E+07              2.82
  24    MMFD    Malignant            Yes   RIC     13          13      4            1.30E+06               2.66E+09              3.31
  25    UD      SCID                 Yes   RIC     8           13      3            8.10E+05               2.31E+07              1.45
  26    MSD     Malignant            Yes   RIC     14          14      0            2.34E+04               8.74E+07              3.57
  27    UD      Malignant            Yes   RIC     13          13      0            4.56E+04               4.15E+08              3.96
  28    MMFD    Fanconi A.           Yes   RIC     8           13      0            1.27E+04               2.05E+07              3.21
  29    MMFD    Malignant            Yes   MA      10          13      3            2.46E+03               5.20E+08              5.32
  30    UD      Malignant            Yes   RIC     22          14      0            1.61E+05               2.32E+08              3.16
  31    UD      Malignant            Yes   RIC     34          27      0            2.31E+05               2.31E+05              0.00
  32    UD      Malignant            No    MA      14          14      0            4.67E+04               7.41E+07              3.20
  33    UD      Malignant            Yes   MA      25          18      2            4.28E+05               1.24E+09              3.46
  34    MSD     Malignant            Yes   MA      19          12      3            6.66E+05               1.25E+06              0.27
  35    MSD     SCID                 Yes   RIC     14          14      4            7.55E+08               1.85E+09              0.39
  36    UD      Malignant            Yes   RIC     10          10      0            3.08E+03               l.72E+05              1.75
  37    UD      Malignant            No    MA      n.a.        9       3            8.24E+05               8.30E+08              3.00
  38    MSD     Malignant            Yes   MA      63          33      0            1.36E+04               l.28E+08              3.97
  39    UD      Malignant            Yes   MA      25          18      1            3.39E+03               8.33E+07              4.39
  40    UD      Malignant            No    MA      13          13      1            6.78E+04               5.21E+08              3.89
  41    UD      Malignant            Yes   MA      25          25      3            9.92E+06               2.14E+08              1.33
  42    MSD     Malignant            No    MA      13          13      3            2.44E+04               1.06E+07              2.64
  43    UD      Malignant            Yes   MA      28          28      4            5.48E+05               6.09E+07              2.05

a

Engraftment at the indicated days after HSCT;

b

DNA copies/ml plasma;

c

highest value within 100 days post-transplant; UD, unrelated donor; MSD, matched sibling donor; MMFD, mismatched family donor; A., anemia; SCID, severe combined immunodeficiency; ATG, anti-thymocyte globulin; Cond., conditioning; RIC, reduced intensity conditioning; MA, myeloablative conditioning; n.a., not available

.

Specific Cell Separation by Centrifugation and Flow Cytometry
-------------------------------------------------------------

Individual leukocyte subsets were isolated from PB or BM via staining for specific cell surface antigens including CD4^+^, CD8^+^, CD19^+^, CD56^+^, CD33^+^, and CD15^+^ as part of routine diagnostics in HSCT recipients at the St. Anna Children's Hospital, Vienna, Austria. Cell sorting was performed on a FACSAria instrument (BD Biosciences) using the FACSDiVa software, as described previously ([@B10]). The purity of individual leukocyte fractions was \>98%. Generally, 4,000 cells from each leukocyte subset were isolated for subsequent analysis. For DNA isolation from plasma, PB samples were centrifuged at 100 *g* for 10 min, and the cell pellets were discarded. Erythrocytes derived from PB specimens of patients from the control group were obtained upon cell sedimentation. The platelet concentrates were centrifuged at 1,600 *g* for 30 min and resuspended in PBS for DNA isolation, as described below. Erythrocyte and platelet numbers were determined by a Sysmex Kx21 Hematology Analyzer (Sysmex).

Isolation of Viral DNA and RNA
------------------------------

The QIAamp DNA Mini Kit (Qiagen) was employed for the isolation of DNA from plasma, PB and individual cell subsets. Extraction of DNA from stool specimens was performed by the QIAamp DNA Stool Mini Kit (Qiagen) according to the manufacturer's recommendations, and viral RNA was isolated with the RNeasy Kit plus (Qiagen), with subsequent DNA digestion with DNase Q1 (Promega). For further real-time quantitative (RQ)-PCR analyses, the RNA was transcribed into cDNA using the MLV reverse transcriptase (Promega).

TTV DNA Detection by RQ-PCR
---------------------------

RQ-PCR targeting the UTR region of the TTV genome was used for virus detection. The PCR assay previously described by [@B20] was modified by adding an additional reverse primer (5′-GGTCCGGCCAGTCC-3) to cover a greater spectrum of TTV strains. Moreover, a Taqman probe labeled with a fluorescence dye and a quencher, but without further modifications (5′FAM-TCAAGGGGCAATTCGGGCT-TAMRA3′), was employed. The detection limit, linearity and reproducibility of the assay were determined by using quantified plasmid preparations containing the UTR region of TTV ([@B19]) (kindly provided by F. Maggi, University of Pisa, Italy) and appropriate standard curves. The consistently achievable detection limit of the assay was 10 TTV DNA copies per PCR reaction. To determine the virus copy numbers per cell, a human single-copy housekeeping gene (beta2-microglobulin) was co-amplified by RQ-PCR in parallel with the virus-specific assay, as described previously ([@B29]). All RQ-PCR analyses were performed on the ABI Prism Fast 7500 instrument (Thermo Fisher Scientific).

TTV RNA Detection by RQ-PCR
---------------------------

RQ-PCR assays exploiting SYBR green were used to analyze the TTV RNA expression. The Maxima SYBR green Master Mix (Thermo Fisher Scientific) with the following oligonucleotides was used: TTV1 forI 5′-GACACAGAACTCACAGCCC-3′, TTV1 forII 5′-GACACTGACGTGACAGCCG-3′, TTV1 rev 5′-GTTAGTGGTGAGCCGAACG-3′. The PCR was performed with 10 pmol of each oligonucleotide targeting the VP1 region of the TTV genotype 1, at an annealing temperature of 60°C, according to the protocol recommended for the Maxima SYBR green Master Mix.

Statistics
----------

Spearman correlation was employed for analysis of the correlation coefficient between TTV levels in plasma and lymphocyte as well as granulocyte counts on days +30, +60, and +100 post-transplant. The calculations were performed by employing the GraphPad Prism 5 software.

Results
=======

Expansion of TTV in Plasma and Stool After HSCT
-----------------------------------------------

Elevated TTV titers were previously described primarily in adult solid organ transplant (SOT) recipients and in a small number of recent studies in patients undergoing HSCT ([@B3]; [@B9]; [@B13]; [@B30]). In the present study, 34 of the 43 pediatric HSCT patients investigated (79%) had the virus detectable in plasma already before transplantation, and all patients tested positive for TTV DNA by day +50 post-transplant, as revealed by RQ-PCR analysis. The TTV DNA copy numbers before HSCT and the highest copy numbers detected in plasma until day +100 post-transplant are shown in Table [1](#T1){ref-type="table"}, along with pertinent patient characteristics including the conditioning regimen, *in vivo* T cell depletion (involving primarily ATG), day of engraftment, and grade of GvHD, if present. In TTV positive patients, the median virus load detected before transplantation and until day +30 post-transplant was 1 × 10E4 DNA copies per ml plasma, with rapidly rising levels after day +30. The peak was generally reached around day +100, with a median of 7 × 10E7 (range: 7 × 10E3 -- 4 × 10E9) virus copies per ml plasma (Figure [1A](#F1){ref-type="fig"}). The TTV DNA copy numbers observed within defined sequential time periods after transplantation were highly variable, occasionally revealing even switches between negativity and positivity, but the patients analyzed invariably tested positive for TTV between days +90 and +200 post-transplant (Figure [1A](#F1){ref-type="fig"}). After day +100, gradually decreasing virus loads were observed, and the median time for returning to pre-transplant TTV levels was 2 years (Figure [1B](#F1){ref-type="fig"}). Monitoring of TTV levels in serial stool samples until day +100 was performed in 21 of the 43 patients investigated, and revealed median virus levels and replication kinetics very similar to the findings in plasma at corresponding time points (Figure [1B](#F1){ref-type="fig"}). A significant age dependency of TTV positivity in plasma before HSCT has been observed revealing a median age of 1.6 years (range: 0.6--12 years) in patients who tested TTV negative pre-transplant, and 9 years (range: 3--18 years) in patients who were TTV positive in plasma already before HSCT (Figure [1C](#F1){ref-type="fig"}, *p* \< 0.01).

![RQ-PCR monitoring of TTV copies in plasma and stool before and after HSCT. RQ-PCR analysis detecting TTV was exploited to analyze the virus load. **(A)** The dot plot depicts the numbers of TTV copies/ml plasma in individual pediatric patients (*n* = 43) during the indicated time periods before and after HSCT. The horizontal bars represent the respective median values. **(B)** The curves reflect the median values of TTV copies per ml plasma (*n* = 43; solid line) or per gram stool (*n* = 21; dashed line) during the indicated observation period. **(C)** The age of patients at the time of transplantation is shown in correlation with TTV negativity and positivity in plasma pre-transplant (*t*-test; *p* \< 0.01).](fmicb-09-02956-g001){#F1}

Delayed Post-transplant Onset of TTV Replication
------------------------------------------------

Based on different studies performed in the adult transplant setting, which indicated the possibility of exploiting the TTV kinetics as a marker for the immune status in HSCT recipients ([@B9]; [@B1]; [@B12]), we have addressed the potential clinical use of TTV monitoring in a cohort of pediatric patients undergoing allogeneic HSCT. During the first month post-transplant, the median TTV DNA copy numbers in plasma remained more or less constant, while the median numbers of generally donor-derived CD4^+^, CD8^+^ cells and granulocytes increased by more than one log within this time interval. Subsequently, after day +30 post-transplant, following T cell and neutrophil engraftment, rapidly rising TTV DNA copy numbers were observed, with peak levels around day +100 (Figure [2A](#F2){ref-type="fig"}). During this time period, the median T cell and granulocyte numbers had already reached plateau levels above 250/μl and 2500/μl blood, respectively. The TTV plasma levels therefore showed no significant correlation with lymphocyte counts between days +30 and +100 post-HSCT (Figures [2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}), and the lack of correlation also applied to the T cell subsets CD4^+^ and CD8^+^ (data not shown). However, the TTV plasma levels correlated significantly with the granulocyte counts on days +30 and +60 (*p* \< 0.05; Figures [2E,F](#F2){ref-type="fig"}), but not on day +100 post-HSCT (Figure [2G](#F2){ref-type="fig"}). There was no correlation between TTV plasma levels at these time points and the absence or presence of GvHD at any level (data not shown).

![Correlation of TTV plasma levels with granulocyte and lymphocyte numbers. Median TTV DNA copy numbers per ml plasma were analyzed by RQ-PCR. **(A)** The kinetics of TTV load (solid line) representative of all 43 patients investigated are shown in relation to the median cell numbers of granulocytes, CD4^+^ and CD8^+^ cells (dashed lines) at the indicated time windows post-HSCT. Spearman correlation of TTV levels and total lymphocyte counts at days **(B)** +30, **(C)** +60, and **(D)** +100 post-HSCT and **(E--G)** granulocyte counts (CD15^+^ cells) at days +30, +60, and +100 post-HSCT, respectively, is shown for the entire cohort of 43 patients. The *p*-values and correlation coefficients (r) are indicated.](fmicb-09-02956-g002){#F2}

Assessment of the TTV Replication Sites and Expansion Kinetics in Transplant Recipients
---------------------------------------------------------------------------------------

To address the possibility that post-transplant replication of TTV occurs in specific nucleated blood cells, different leukocyte subsets were isolated by flow-sorting from PB or BM of 19 pediatric allogeneic HSCT recipients displaying a donor chimerism exceeding 98% beyond day +50 post-transplant. Testing for the presence of TTV DNA in individual leukocyte subsets was performed by RQ-PCR analysis of DNA derived from 4,000 cells per subset. While T cells including the CD4^+^ and CD8^+^ subpopulations, B cells and NK cells did not show any evidence for the virus, granulocytes (CD15^+^) isolated either from PB or BM tested invariably positive in post-transplant samples of all patients analyzed (Figure [3A](#F3){ref-type="fig"}). Monocytes derived from BM specimens revealed TTV-positive results in three of the 19 patients analyzed, but the median copy numbers were too low (\<0.6 copies/cell) to generate a visible signal in the panel displayed (Figure [3A](#F3){ref-type="fig"}). For the assessment of TTV positivity in individual leukocyte subsets, it was necessary to consider that the purity of flow-sorted cell fractions was generally \>98%, thus enabling low-level contamination with other leukocyte subsets. Since contamination with TTV-positive granulocytes could have resulted in false-positive test results for individual leukocyte fractions, low-level positivity below 2% of the TTV DNA copy numbers detected in leukocyte subsets other than granulocytes was regarded as a negative result. However, the three patients who tested TTV-positive in the monocyte fractions showed virus copy numbers above the indicated threshold, suggesting the presence of true positive test results. The kinetics of increasing TTV replication in granulocytes during the first 100 days after transplantation revealed median virus copy numbers ranging from 0.1 to 40 per cell in PB and 1 to 63 per cell in BM (Figure [3B](#F3){ref-type="fig"}). The replication of the virus in granulocytes is documented by a roughly two-log increase of median virus copy numbers per cell between days +30 and +100 after allogeneic HSCT (Figure [3B](#F3){ref-type="fig"}). Before day +30 post-transplant, TTV tested either negative or only low-positive in granulocytes, although the cell numbers of this leukocyte subset expanded rapidly above 500 granulocytes per μl PB already between 2 and 4 weeks after transplantation in 17 of the 19 patients analyzed (Figure [3B](#F3){ref-type="fig"}). In addition expression of viral RNA was assessed in flow-sorted granulocytes derived from five HSCT-recipients between 40 to 100 days post-transplant. Expression of TTV RNA was detected in all instances. Control experiments confirmed the absence of TTV DNA in the RNA samples analyzed (data not shown).

![TTV detection in leukocyte subsets and virus replication kinetics after transplantation. Leukocyte subsets including CD4^+^, CD8^+^, CD19^+^, CD15^+^ (granulocytes: Gran), CD33^+^ (monocytes: Mono) and CD56^+^ (natural killer cells: NK) were isolated by flow sorting from peripheral blood (PB) and bone marrow (BM) of 19 pediatric HSCT recipients. Individual cell subsets were tested for the presence and quantity of virus copies by a TTV-specific RQ-PCR assay. **(A)** The median of the peak TTV copy numbers per cell determined in the patients investigated is shown for the different leukocytes subsets. **(B)** The TTV replication kinetics in granulocytes isolated from PB and BM of the 19 patients investigated is shown by the median virus copy numbers per cell at the indicated time points post-HSCT. The *y*-axis on the right side indicates the granulocyte numbers per μl PB.](fmicb-09-02956-g003){#F3}

Persistence of TTV in Plasma and Blood Cells
--------------------------------------------

To assess whether the observed TTV replication in granulocytes of pediatric HSCT recipients might correlate with transplant-independent persistence of the virus in PB, targeted testing was performed in a control cohort of 30 hospitalized children with non-malignant diseases who were no candidates for allogeneic stem cell transplantation. Testing of whole PB and plasma samples for TTV sequences by RQ-PCR revealed presence of the virus in 27/30 (90%) of the PB specimens and in 22/30 (73%) of the plasma specimens analyzed. In all instances, the virus loads detected in whole PB samples were considerably higher than in plasma samples of the same patients, suggesting common TTV association with cellular elements (Figure [4A](#F4){ref-type="fig"}). The median TTV DNA copy numbers in PB were 1.0E+05/ml (range: 0.0 to 7.2E+06 copies/ml), and 5.4E+03/ml (range: 0.0 to 3.1E+06 copies/ml) in plasma. In 5/30 patients who tested positive for TTV only in whole PB but not in plasma, the virus copy numbers were rather low, ranging between 1E+3 and 5E+4 per ml (Figure [4A](#F4){ref-type="fig"}). In patients with TTV positivity both in whole PB and plasma, the median difference in virus copy numbers was \>1 log~10~ (range: 0.31--1.87 log~10~). To assess the presence of TTV in various leukocyte subsets, T and B lymphocytes (CD4^+^, CD8^+^, and CD19^+^), NK-cells, monocytes and granulocytes were isolated from PB of all 30 patients by flow-sorting, and 4,000 cells of each subset were used for DNA extraction and RQ-PCR analysis. Based on the observation of TTV positivity in granulocytes and monocytes of HSCT recipients, an additional 100,000 cells of these leukocyte subsets and T cells were collected to increase the sensitivity of virus detection. Of the cell types analyzed, only granulocytes tested positive for TTV, and the virus was detected in DNA samples derived from two additional patients in whom TTV was undetectable in DNA isolated from 4,000 cells. However, only 10/30 (33%) patients from the control cohort had TTV detectable in granulocytes, and the virus copy numbers were lower than in transplant recipients (median: 0.5 TTV copies per cell; range: 0.01 to 8 TTV copies per cell). In line with this observation, 5 of the 19 transplant recipients investigated (26%) were positive for TTV in granulocytes already within the first month post-HSCT, and the intracellular virus copy numbers were similar in both indicated settings (Figures [4B,C](#F4){ref-type="fig"}).

![TTV in peripheral blood and granulocytes in the pediatric control cohort. **(A)** Copy numbers of TTV in peripheral blood and plasma of 30 non-oncological control patients. **(B+C)** Comparison between the control group and the HSCT recipients until days +30 and +100. **(B)** TTV copies per granulocyte (CD15^+^ cells), **(C)** patient numbers displaying TTV positive granulocytes.](fmicb-09-02956-g004){#F4}

In order to address the notion that granulocytes are not the only TTV reservoir in PB of immunocompetent children, erythrocyte and thrombocyte preparations were investigated for presence of the virus. Erythrocytes isolated from ten patients of the control cohort, seven of whom had tested TTV-positive in leukocyte preparations, tested negative for the virus. Moreover, platelet concentrates from 14 different healthy donors were analyzed for the presence of TTV, and the virus was detected in six instances (43%). The median virus copy number per platelet determined by RQ-PCR was 0.6 (range 0.2--7.5). To determine whether the TTV positivity found in platelet concentrates might be attributable to residual plasma present in the preparations, densely packed platelets derived by centrifugation of the concentrates were tested in parallel by RQ-PCR and revealed identical results in three of the six positive samples, suggesting that platelets can carry either internalized or adherent particles of the virus. The distribution and quantity of TTV in different PB cells are summarized in Table [2](#T2){ref-type="table"}.

###### 

Distribution and quantity of TTV in plasma and in leukocyte subsets.

  Patients           Cell type/material          TTV positive   TTV copies/cell or ml^b^
  ------------------ --------------------------- -------------- --------------------------
  HSCT patients^a^   Plasma                      43/43 (100%)   7.46E+06 (0--1.85E+09)
                     Granulocytes                19/19 (100%)   29.82 (0.1--3.87E+03)
  Control cohort     Plasma                      22/30 (73%)    5.43E+03 (0--3.12E+06)
                     Granulocytes                10/30 (33%)    0.45 (0--7.9)
                     T, B, NK cells. Monocytes   0/30 (0%)      0
                     Erythrocytes                0/10 (0%)      0
                     Platelets                   6/14 (44%)     0.6 (0--7.5)

a

50 days post-HSCT;

b

median (range)

.

Discussion
==========

Several studies suggested a correlation of increasing TTV levels in PB and plasma with the immune status of patients after transplantation, and indicated the possibility of exploiting post-transplant quantitative TTV analyses in SOT and HSCT recipients particularly as a surrogate marker for immune reconstitution ([@B9]; [@B18]; [@B13]; [@B1]; [@B12]; [@B30]). However, data available to date show a rather unclear relationship between TTV and the immune system, thus rendering conclusions concerning the relevance of TTV monitoring difficult ([@B30]). Our data revealed no significant correlation between the lymphocyte counts and TTV levels at +30, +60, or +100 days post-transplant. The presence of constant or even slightly decreasing TTV levels during the first month post-transplant documented in the present study has also been described in a recent report ([@B1]), however, other observations indicated an increase of TTV immediately after transplantation ([@B13]). Data on the incidence and the potential impact of TTV expansion in pediatric transplant recipients have not been available, with the exception of a single report on high expression levels of various cytokines and the chemokine MCP-3 in association with TTV-positivity ([@B31]). Nevertheless, the putative role of the virus or the potential clinical use of its monitoring in the pediatric post-transplant setting remains enigmatic.

In agreement with earlier studies, our analysis of plasma specimens derived from HSCT recipients showed increasing TTV loads during the first 3 to 4 months post-transplant ([@B18]; [@B13]; [@B30]), followed by gradually decreasing virus copy numbers in plasma to pre-transplantation levels over a period of about 2 years. The observed TTV kinetics in plasma might therefore reflect a correlation of the virus copy numbers with impairment of the immune system and its recovery post-transplant. It might be of relevance to consider that the variety of TTV genotypes increases in transplant recipients ([@B9]) as a result of allografting and the common transfusion of blood products from various donors during the post-transplant course. Although it is unknown whether contemporaneous presence of multiple TTV genotypes in the circulation might have any impact on patients undergoing allogeneic HSCT, an effect on TTV replication during immunosuppression, particularly in patients without detectable TTV before transplantation, cannot be entirely excluded. Moreover, the absence of TTV in children below the age of 3 years might reflect the first contact and infection with the virus.

We observed elevated TTV copy numbers not only in plasma but also in stool specimens tested at the same time points, which might be attributable to the shedding of leukocytes carrying the virus into the intestines. This finding supported the possibility that TTV replication occurs in specific leukocyte subsets, and this notion was assessed by testing individual cell types isolated by flow-sorting at different time points after HSCT. Our data obtained in pediatric patients show that replication of the virus occurs in CD15^+^ cells representing neutrophilic granulocytes, the most abundant fraction of the granulocytes, and expansion of the virus generally starts 1 month after transplantation, upon engraftment of these cells. This finding might suggest that sufficiently high granulocyte numbers might be a prerequisite for efficient TTV expansion post-transplant, and could therefore provide a possible explanation for the delayed onset of rapid replication of the virus. Indeed, TTV copy numbers revealed a significant correlation with the number of neutrophils at +30 and +60 days after HSCT. A previous study reported a drop of TTV levels in patients treated with anti-thymocyte globulin (ATG) which was more pronounced than in patients treated with basiliximab, a weaker T lymphocyte inhibiting antibody. The possible effect of anti-T lymphocyte drugs on TTV levels provided the basis for the suggestion that T lymphocytes are the host cells for TTV replication ([@B8]). This concept is not supported by our findings which did not reveal presence of the virus in any lymphocyte subset isolated from PB during the post-transplant course. In partial agreement with our observations, [@B28] found the highest TTV levels in granulocytes derived from a small number of individuals and two log~10~ lower levels in other hematopoietic cells. Our findings indicated not only the presence of the virus in granulocytes but revealed a clear increase of TTV copy numbers in these cells with peak levels around 100 days post-transplant. It is necessary to consider that the life span of peripheral granulocytes is very short, generally within the range of a few days only, but our analyses of myeloid cells derived from the bone marrow also showed evidence for the virus. Although granulocytes are an important site of TTV replication, as demonstrated by the data presented, they may not serve as host cells for persistence of the virus. The exploitation of diverse cell types for persistence and replication of individual viruses is a well-known phenomenon. Viral persistence requires the infection of cells with a long life span, whereas replication, which is commonly associated with cell lysis, can occur in short-lived cell types providing the environment conducive for viral multiplication. In line with this notion, similar studies on human adenoviruses performed by us and others showed persistence of the virus in tonsillar and mucosal T lymphocytes ([@B11]; [@B25]; [@B15]), whereas replication occurred in epithelial cells of the lungs or the intestine ([@B16]; [@B14]). Although we did not find TTV in T cells isolated by flow-sorting from PB, its persistence in these cells cannot be excluded because virus-infected T cells may not occur at sufficiently high frequencies in the circulation, and the intracellular virus concentrations may be very low.

The observation of rather constant TTV plasma levels during the first month post-transplant, the detection of rising plasma virus levels with documented replication in granulocytes during the ensuing 2 to 3 months, and the subsequent gradual return of the virus copy numbers to pre-transplant levels in the pediatric HSCT recipients investigated prompted us to compare the findings to a control cohort of immunocompetent children. The occurrence of TTV positivity in the plasma of patients prior to HSCT reflecting the state of persistence was very similar to the control group, revealing 79 and 73% of virus-positive individuals, respectively. However, TTV was identified in granulocytes in only one third of the children within the control cohort, while all HSCT recipients invariably tested positive for the virus in granulocytes by day +50 post-transplant. This implies that the virus is also carried by other cells in the immunocompetent control patients. However, in agreement with the findings in HSCT recipients, we could not detect the virus in isolated lymphocytes. In search for a carrier of TTV in PB, we identified presence of the virus in plasma-depleted platelet concentrates, raising the possibility that TTV may be taken up or adhere to thrombocytes. This notion is supported by the fact that several platelet receptors are known to bind viruses such as Epstein-Barr virus, hepatitis virus C, adenovirus, rotavirus, or human immunodeficiency virus ([@B4]), but little information is available on the interactions between platelets and viruses. The drop of platelet counts associated with severe bleeding observed during some viral infections might be due to platelet destruction mediated by antibodies, by platelet-leukocyte aggregation or by direct viral effects on platelets. However, the assessment of possible effects mediated by the presence of TTV in or on platelets will require further investigation. Ongoing studies addressing the interactions of TTV with the human host will undoubtedly unveil the potential secrets of this currently enigmatic virus.
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